newsfilter
← Latest News
Business Wire·

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

  • Janux Therapeutics has dosed the first patient in a Phase 1 trial for JANX013, a PSMA-targeted tumor-activated CD28 co-stimulatory bispecific
  • The trial evaluates JANX013 in combination with JANX007 in patients with metastatic castration-resistant prostate cancer (mCRPC)
  • JANX013 utilizes proprietary tumor-activation technology to deliver CD28 co-stimulation selectively within the tumor microenvironment
  • The study aims to enhance the durability of anti-tumor immune responses while minimizing systemic CD28 activation
  • Trial NCT07813637 is a first-in-human, open-label, multicenter study assessing safety, tolerability, pharmacokinetics, pharmacodynamics, & preliminary efficacy
  • Researchers will evaluate biomarkers of immune activation, including T-cell expansion & persistence, to characterize the effects of tumor-restricted co-stimulation
  • Janux intends to evaluate JANX013 with additional candidates from its prostate cancer portfolio over time